LCLAT1 and metabolic dysfunction-associated steatotic liver disease: Furthermore, the targeted deletion of lysocardiolipin acyltransferase 1 (ALCAT1) has been shown to reverse mitophagy arrest and mitigate mitochondrial dysfunction in MASLD.